Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS with Lumason for Liver Lesion Detection in Cirrhosis
NCT03407001Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulfur hexafluoride in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres compared to B-mode non-contrast enhanced ultrasound for liver lesion detection up to 3 years. Started Jan 2018; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03407001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407001.